BioMarin Pharmaceuticals
BMRN • NASDAQ
BioMarin Pharmaceuticals is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Alexander Hardy, with a market cap of $10.4B.
CEOAlexander Hardy
Next Earnings
Upcoming earnings announcement for BioMarin Pharmaceuticals
Date
Thursday, April 30, 2026 (in a month)
Timing
After Market Close (4:00 PM New York)
Fiscal Period
Q1 2026
EPS Estimate
$0.96
Revenue Estimate
$763.4M
Earnings History
Past 12 earnings reports for BioMarin Pharmaceuticals
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Feb 23, 2026 | Q4 2025 | $0.46Est: $0.36 | +27.8% | $875.0MEst: $832.9M | +5.1% |  10-K |
| Oct 27, 2025 | Q3 2025 | $0.12Est: $0.51 | -76.5% | $776.1MEst: $781.9M | -0.7% | — |
| Aug 4, 2025 | Q2 2025 | $1.44Est: $0.93 | +54.8% | $825.4MEst: $763.5M | +8.1% | 10-Q |
| May 1, 2025 | Q1 2025 | $1.13Est: $0.71 | +59.2% | $745.1MEst: $740.7M | +0.6% | 10-Q |
| Feb 19, 2025 | Q4 2024 | $0.92Est: $0.74 | +24.3% | $747.0MEst: $711.1M | +5.1% | 10-K |
| Oct 29, 2024 | Q3 2024 | $0.91Est: $0.52 | +75.0% | $745.7MEst: $700.1M | +6.5% | 10-Q |
| Aug 5, 2024 | Q2 2024 | $0.96Est: $0.35 | +174.3% | $712.0MEst: $661.2M | +7.7% | 10-Q |
| Apr 24, 2024 | Q1 2024 | $0.71Est: $0.34 | +108.8% | $648.8MEst: $651.8M | -0.5% | 10-Q |
| Feb 22, 2024 | Q4 2023 | $0.49Est: $0.23 | +113.0% | $646.2MEst: $636.7M | +1.5% | 10-K |
| Nov 1, 2023 | Q3 2023 | $0.46Est: $0.22 | +109.1% | $581.3MEst: $608.3M | -4.4% | — |
| Jul 31, 2023 | Q2 2023 | $0.54Est: $0.47 | +14.9% | $595.3MEst: $591.5M | +0.6% | 10-Q |
| Apr 26, 2023 | Q1 2023 | $0.60Est: $0.18 | +233.3% | $596.4MEst: $570.6M | +4.5% | 10-Q |